GB2304047A - Pharmaceutical compositions containing cytokines - Google Patents

Pharmaceutical compositions containing cytokines Download PDF

Info

Publication number
GB2304047A
GB2304047A GB9516287A GB9516287A GB2304047A GB 2304047 A GB2304047 A GB 2304047A GB 9516287 A GB9516287 A GB 9516287A GB 9516287 A GB9516287 A GB 9516287A GB 2304047 A GB2304047 A GB 2304047A
Authority
GB
United Kingdom
Prior art keywords
wounds
healing
composition
cytokine
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9516287A
Other languages
English (en)
Other versions
GB9516287D0 (en
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
Victoria University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester filed Critical Victoria University of Manchester
Priority to GB9516287A priority Critical patent/GB2304047A/en
Publication of GB9516287D0 publication Critical patent/GB9516287D0/en
Priority to EP96926507A priority patent/EP0871473B1/en
Priority to PCT/GB1996/001930 priority patent/WO1997005894A1/en
Priority to AT96926507T priority patent/ATE229814T1/de
Priority to DK96926507T priority patent/DK0871473T3/da
Priority to AU66660/96A priority patent/AU719089B2/en
Priority to JP50824697A priority patent/JP4050317B2/ja
Priority to PT96926507T priority patent/PT871473E/pt
Priority to ES96926507T priority patent/ES2187665T3/es
Priority to CA2229078A priority patent/CA2229078C/en
Priority to US09/011,027 priority patent/US6387364B1/en
Priority to DE69625516T priority patent/DE69625516T2/de
Priority to ZA9606744A priority patent/ZA966744B/xx
Publication of GB2304047A publication Critical patent/GB2304047A/en
Priority to US10/082,221 priority patent/US7052684B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
GB9516287A 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines Withdrawn GB2304047A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
ZA9606744A ZA966744B (en) 1995-08-09 1996-08-08 Pharmaceutical composition.
JP50824697A JP4050317B2 (ja) 1995-08-09 1996-08-08 Ｉｌ−１０含有医薬組成物
ES96926507T ES2187665T3 (es) 1995-08-09 1996-08-08 Uso de la il-10 para curar heridas con una cicatrizacion reducida.
AT96926507T ATE229814T1 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
DK96926507T DK0871473T3 (da) 1995-08-09 1996-08-08 Anvendelse af IL-10 til sårheling med reduceret ardannelse
AU66660/96A AU719089B2 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing IL-10
EP96926507A EP0871473B1 (en) 1995-08-09 1996-08-08 Use of il-10 for wound healing with reduced scarring
PT96926507T PT871473E (pt) 1995-08-09 1996-08-08 Utilizacao de il-10 para curar feridas com cicatrizacao reduzida
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10
CA2229078A CA2229078C (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10
US09/011,027 US6387364B1 (en) 1995-08-09 1996-08-08 Methods of healing wounds and fibrotic disorders using IL-10
DE69625516T DE69625516T2 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
US10/082,221 US7052684B2 (en) 1995-08-09 2002-02-26 Methods of healing wounds and fibrotic disorders using IL-10

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines

Publications (2)

Publication Number Publication Date
GB9516287D0 GB9516287D0 (en) 1995-10-11
GB2304047A true GB2304047A (en) 1997-03-12

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9516287A Withdrawn GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines

Country Status (13)

Country Link
US (2) US6387364B1 (enExample)
EP (1) EP0871473B1 (enExample)
JP (1) JP4050317B2 (enExample)
AT (1) ATE229814T1 (enExample)
AU (1) AU719089B2 (enExample)
CA (1) CA2229078C (enExample)
DE (1) DE69625516T2 (enExample)
DK (1) DK0871473T3 (enExample)
ES (1) ES2187665T3 (enExample)
GB (1) GB2304047A (enExample)
PT (1) PT871473E (enExample)
WO (1) WO1997005894A1 (enExample)
ZA (1) ZA966744B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017558A3 (en) * 1999-09-08 2001-09-27 Schering Corp Novel uses of mammalian ccr6 receptors and related reagents

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0941108T3 (da) * 1996-12-04 2002-11-18 Renovo Ltd Sårheling og behandling af fibrose
AU6045198A (en) * 1997-02-05 1998-08-25 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
WO2003062373A2 (en) * 2001-10-18 2003-07-31 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
ES2375565T3 (es) 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
WO2009120799A2 (en) * 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
ES2957546T3 (es) 2008-12-17 2024-01-22 Merck Sharp & Dohme Producción de mono- y di-PEG-IL10; y usos
NZ600583A (en) * 2009-02-24 2013-08-30 Healor Ltd Visfatin therapeutic agents for the treatment of acne and other conditions
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
EP2691515A2 (en) * 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
WO1992011861A1 (en) * 1991-01-10 1992-07-23 Schering Corporation Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
WO1993019770A1 (en) * 1992-04-06 1993-10-14 Isis Innovation Limited Compositions for the treatment of acute or chronic inflammation
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
EP0280560B1 (en) 1987-02-27 1994-05-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Membrane structure coated with low pI protein and methods of making and using
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
ES2124702T3 (es) 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
WO1993004164A1 (en) 1991-08-26 1993-03-04 THE STATE OF OREGON acting by and through THE STATE OF BOARD OF HIGHER EDUCATION on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
IL110413A0 (en) 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
EP0968723B1 (en) * 1994-03-29 2009-07-01 Renovo Limited Healing of wounds or fibrotic disorders using at least one agent against a growth factor
CA2205572A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
GB9516012D0 (en) 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
WO1992011861A1 (en) * 1991-01-10 1992-07-23 Schering Corporation Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
WO1993019770A1 (en) * 1992-04-06 1993-10-14 Isis Innovation Limited Compositions for the treatment of acute or chronic inflammation
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017558A3 (en) * 1999-09-08 2001-09-27 Schering Corp Novel uses of mammalian ccr6 receptors and related reagents

Also Published As

Publication number Publication date
AU719089B2 (en) 2000-05-04
CA2229078C (en) 2010-04-20
US7052684B2 (en) 2006-05-30
EP0871473A1 (en) 1998-10-21
US20020128447A1 (en) 2002-09-12
AU6666096A (en) 1997-03-05
PT871473E (pt) 2003-03-31
CA2229078A1 (en) 1997-02-20
ZA966744B (en) 1998-02-09
EP0871473B1 (en) 2002-12-18
DK0871473T3 (da) 2003-04-14
JP4050317B2 (ja) 2008-02-20
US6387364B1 (en) 2002-05-14
JPH11510505A (ja) 1999-09-14
ATE229814T1 (de) 2003-01-15
DE69625516T2 (de) 2003-09-25
GB9516287D0 (en) 1995-10-11
WO1997005894A1 (en) 1997-02-20
DE69625516D1 (de) 2003-01-30
ES2187665T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
US7052684B2 (en) Methods of healing wounds and fibrotic disorders using IL-10
Roberts et al. Physiological actions and clinical applications of transforming growth factor-β (TGF-β)
DE69518156T2 (de) Immunomodulatoren
Armour et al. Cellular and molecular pathology of HTS: basis for treatment
Bessis et al. The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis
EP0968723B1 (en) Healing of wounds or fibrotic disorders using at least one agent against a growth factor
DE60208692T2 (de) Interleukin -18 mutantenproteine, deren herstellung und verwendung
DE69119879T2 (de) Epitheliocytenwachstumsbeschleuniger
JP2000503652A (ja) 合成ｉｌ―１０類似体
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
DE69028101D1 (de) Melaninkonzentrierende hormone und dns die diese expremieren
US7220413B2 (en) Pharmaceutical composition containing inhibitors of interferon-γ
JP6005736B2 (ja) Ｉｌ−１２を用いる皮膚損傷の軽減
DE69626050T2 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
EP2572724A1 (de) Behandlung von Fibrosen und Lebererkrankungen
US20080031879A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304045A (en) Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
AU747598B2 (en) Pharmaceutical composition containing stimulators of interferon-gamma
WO2000057902A1 (en) Method and pharmaceutical composition for wound healing
HK1024419A (en) Healing of wounds or fibrotic disorders using at least one agent against a growth factor
HK1023516B (en) Pharmaceutical composition containing stimulators of interferon-gamma

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)